Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Protocol Title: Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity

Next Previous
Trial Profile

Protocol Title: Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cagrilintide/semaglutide (Primary) ; Cagrilintide; Semaglutide
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Acronyms REDEFINE 1
  • Sponsors Novo Nordisk

Most Recent Events

  • 24 Jun 2025 According to Novo Nordisk media release, Timothy Garvey, MD, professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham, is the lead investigator in this study.
  • 24 Jun 2025 According to Novo Nordisk media release, results from this study along with REDEFINE 2 study were presented on 22 June 2025 during a scientific symposium at the American Diabetes Association's (ADA) 85th Scientific Sessions and published in The New England Journal of Medicine (NEJM).
  • 24 Jun 2025 Results presented in the Novo Nordisk Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top